Paris – 28.05.2026: In a significant development for obesity treatment in France, Health Minister Stéphanie Rist announced today that the medications Wegovy and Mounjaro will now be reimbursed. This decision marks an important step in the fight against obesity, which affects more than eight million people in France.
Wegovy, a drug from the Danish pharmaceutical group Novo Nordisk, had not been reimbursed in France since its launch in October 2024 and cost patients between 274 and 365 euros per month. With the new reimbursement policy, the price for the first three doses is set at 146.91 euros per month, representing a considerable saving for patients.
The decision to reimburse Wegovy and Mounjaro was made following intense negotiations between the French Ministry of Health and the manufacturers. These discussions focused on establishing a fair price and determining the reimbursement rate by the state health insurance. Although the exact details of the agreement have not yet been disclosed, the reimbursement is expected to take effect in the second half of 2026.
The reimbursement of these medications is anticipated to have a significant impact on obesity treatment in France. Experts estimate that the annual cost of the reimbursement will be around 100 million euros. This investment is considered necessary to manage the rising health costs associated with obesity and to improve the quality of life for affected patients.
Novo Nordisk has welcomed the French government’s decision and highlighted that the reimbursement of Wegovy represents an important advance in the fight against obesity. Additionally, the company has announced the reduction of the price of Wegovy in France to 146.91 euros per month for the first three doses, in order to further increase access to the medication.
The introduction of reimbursement for Wegovy and Mounjaro is seen by health experts as a step in the right direction to improve obesity treatment in France. However, it is emphasized that a comprehensive strategy is required which includes, besides medical therapies, prevention measures and the improvement of the population’s eating habits.
The French government plans to inform the public extensively in the coming weeks about the details of the reimbursement and the conditions for prescribing Wegovy and Mounjaro. Patients interested in receiving treatment with these medications should consult their general practitioner or specialist for more information and to discuss the most suitable therapeutic option for them.
The decision to reimburse Wegovy and Mounjaro in France is considered a significant step in the fight against obesity and could serve as a model for other European countries facing similar challenges. It remains to be seen how this decision will affect the prevalence of obesity and the associated health costs in France.
Dieser Artikel wurde mit Hilfe künstlicher Intelligenz erstellt.